Oral hyaluronic acid

Hyaluronic acid is a major component of synovial fluid and cartilage matrix, which makes swallowing it feel intuitive. The intuition doesn't survive pharmacology: intact high-molecular-weight HA is barely absorbed, so a direct "replenishment" story is implausible. What happens instead has been traced in rats — 300 kDa hyaluronan is degraded to oligosaccharides by intestinal bacteria, absorbed in the large intestine, and distributed onward as di-, tetra- and polysaccharides. The polymer does not cross; fragments do. The proposed mechanism is indirect — hyaluronan binding intestinal TLR4, which in a mouse model raised IL-10 and SOCS3 and lowered pleiotrophin — demonstrated in animals, not in humans. Marketing claims about molecular weight ("low MW absorbs better") outrun the evidence in both directions.

The trials

Tashiro 2012 is the longest and most cited: 60 Japanese adults with knee OA took 200 mg/day of high-molecular-weight HA or placebo for 12 months, with both groups doing daily quadriceps exercise, and 38 reached the analysis. Symptom scores (JKOM) improved in both arms and did not differ between them at any time point, nor did the pain-and-stiffness subscale; the difference appeared only in the subgroup aged 70 or younger, at two and four months, in a 60-person trial with an exercise co-intervention. The authors are employees of Kewpie Corporation, an HA manufacturer.

Kalman 2008 is the closest thing to independent US data, funded by the extract's maker but run by a contract site: a 20-person pilot of a chicken-comb extract (80 mg/day) over 8 weeks. Its WOMAC pain change was the same in both arms (−4.1 against −4.0), its SF-36 bodily-pain difference missed significance, and every between-group comparison was null; the authors framed it as preliminary.

The field's main review tabulates 13 reports, every one of them positive, at 48–240 mg/day of HA — seven on symptoms, four on effusion or inflammation, three on muscle strength, and one on a urinary bone marker in athletes. That review was written by the same Kewpie-affiliated group. Thirteen for thirteen in small sponsor-run studies says as much about who runs and publishes these trials as about the molecule.

Oral against injected hyaluronic acid

Evidence for oral HA is categorically weaker than for intra-articular HA injections — different route, different literature, different confidence, so the injection data cannot be borrowed on the supplement's behalf. There are no structural outcomes, no large independent trial, and nothing prominent registered. Combination products (HA + collagen + chondroitin) dominate retail shelves, and attributing benefit within those blends is impossible.

One more absence worth naming plainly, because its shape is easy to mistake: there is no meta-analysis of oral hyaluronic acid for knee osteoarthritis. Searching for one returns analyses of intra-articular HA, PRP and stem cells instead. The paper most often cited as the field's systematic review is a narrative review, four of whose nine authors work for a company selling oral HA. And when an independent meta-analysis of 20 different supplements across 69 trials ranked what works, oral HA was not among the agents showing clinically important effects.

The one place oral HA looks better is unexpected and indirect: in the sole bone-broth animal study with a skeletal endpoint, the fraction containing hyaluronan and chondroitin sulfate was the active one, improving bone mineral density in ovariectomised rats. Bone rather than cartilage, rats rather than people — but it is a rare instance of HA being isolated as the constituent doing the work rather than assumed to be.

Dose & practical notes

Trialed doses run 48–240 mg/day of HA, with 200 mg/day for 12 months in the flagship study. Where effects were reported, they accrued over months, not weeks. Products vary in source (microbial fermentation versus rooster comb) and molecular weight; no clinical data establish the superiority of any format.

Safety

No safety signals in trials up to 12 months. HA is a normal dietary and endogenous molecule, and adverse events matched placebo. Theoretical concerns raised about HA in tumor biology have no clinical supplement data behind them, and there are no established drug interactions.

What I take from it

The trials exist, they point the same way, and the molecule is safe — which is why this sits in promising rather than lower. But nearly the whole evidence base is manufacturer-authored, the best trial's headline is a subgroup result, and the one US pilot, funded by the extract's maker, was too small to conclude anything. An independent, adequately powered trial would settle the question; none has yet been run or registered.